REDWOOD CITY, Calif.,
Dec. 18, 2018 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced it has been selected for
addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). AcelRx's
addition to the NBI will become effective prior to market open on
Monday, December 24, 2018.
The NASDAQ Biotechnology Index (NBI) contains securities of
NASDAQ-listed companies that meet certain eligibility criteria, and
are classified according to the Industry Classification Benchmark
as either Biotechnology or Pharmaceuticals. These requirements
include minimum market capitalization, and average daily trading
volume. The index is re-ranked annually and serves as the basis for
the iShares NASDAQ Biotechnology Index Fund.
For more information about the NBI
visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S., DSUVIA (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO in Europe,
indicated for the management of acute pain severe enough to require
an opioid analgesic for adult patients in certified medically
supervised healthcare settings, and one product candidate,
Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg)
being developed as an innovatively designed patient-controlled
analgesia (PCA) system for reduction of moderate-to-severe acute
pain in medically supervised settings. DZUVEO and Zalviso are both
approved products in Europe. For additional information
about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-added-to-the-nasdaq-biotechnology-index-nbi-300767895.html
SOURCE AcelRx Pharmaceuticals, Inc.